Results 71 to 80 of about 1,268 (176)

A study on the activation peptide released from procarboxypeptidase B (CAPAP) and anionic trypsinogen in patients with acute abdominal disorders of non-pancreatic origin [PDF]

, 2003
Background: The activation peptide released from procarboxypeptidase B, CAPAP, is a marker of the activation of pancreatic enzymes in acute pancreatitis while anionic trypsinogen (AT) levels in urine relate to leakage of unactivated proenzymes.
Appelros, Stefan, Appelros, Stefan,, Christophe A. Müller, Borgström, Anders,, Waldemar Uhl, Borgström, Anders, Markus W. Büchler, Buchler, MW, Anders Borgström, Muller, CA, Stefan Appelros, Lund University., Uhl, W   +12 more
core   +1 more source

The Potential Ability of Betulinic Acid to Prevent Experimentally Induced Acute Pancreatitis in Rats

Basic &Clinical Pharmacology &Toxicology, Volume 136, Issue 6, June 2025.
ABSTRACT Acute pancreatitis (AP) is a serious pancreatic inflammatory disease that results in pancreatic enzyme activation and autodegradation. Betulinic acid (BA), a pentacyclic triterpene of natural origin that was isolated from several plants, has anti‐inflammatory, immunomodulatory and antioxidant effects that can help with AP.
Guler Yenice, Seckin Ozkanlar, Ismail Bolat, Serkan Yildirim   +3 more
wiley   +1 more source

Meconium Peritonitis in the Newborn with Cystic Fibrosis and Negative Neonatal Screening for Immunoreactive Trypsinogen: Clinical Case

Вопросы современной педиатрии
Background. Meconium ileus is one of the manifestations of cystic fibrosis. It is characterized by intestinal obstruction with viscous meconium leading to perforation and peritonitis.
Naila R. Pimenova, Elena I. Kashirskaya, Diana F. Sergienko, Dmitry A. Molev, Olga A. Tyurina, Anastasia V. Alekseeva, Sergey V. Chukarev   +6 more
doaj   +1 more source

Critical Issues in the Management of CRMS/CFSPID Children: A National Real‐World Survey

Pediatric Pulmonology, Volume 60, Issue 1, January 2025.
ABSTRACT Background Notwithstanding guidance from the European Cystic Fibrosis (CF) Society (ECFS) neonatal screening (NBS) working group, significant variation persists in the evaluation and management of Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) subjects, leaving many aspects of care under debate. This study reports the results
Vito Terlizzi, Cristina Fevola, Santiago Presti, Laura Claut, Maura Ambroni, Maria Adelaide Calderazzo, Irene Esposito, Benedetta Fabrizzi, Giuseppina Leonetti, Mariangela Lombardo, Massimo Maschio, Nicola Palladino, Francesca Pauro, Giovanna Pisi, Pietro Ripani, Mirco Ros, Novella Rotolo, Donatello Salvatore, Angela Sepe, Lisa Termini, Silviana Timpano, Patrizia Troiani, Pamela Vitullo, Maurizio Zanda, Francesco Blasi, Carlo Castellani   +25 more
wiley   +1 more source

Cystic Fibrosis Newborn Screening in Portugal: PAP Value in Populations with Stringent Rules for Genetic Studies

International Journal of Neonatal Screening, 2018
Newborn screening (NBS) for cystic fibrosis (CF) has been shown to be advantageous for children with CF, and has thus been included in most NBS programs using various algorithms.
Ana Marcão, Celeste Barreto, Luísa Pereira, Luísa Guedes Vaz, José Cavaco, Ana Casimiro, Miguel Félix, Teresa Reis Silva, Telma Barbosa, Cristina Freitas, Sidónia Nunes, Verónica Felício, Lurdes Lopes, Margarida Amaral, Laura Vilarinho   +14 more
doaj   +1 more source

Disparities and therapeutic advances in cystic fibrosis

Pediatric Pulmonology, Volume 59, Issue 12, Page 3812-3818, December 2024.
Abstract Cystic fibrosis (CF) has seen a multitude of therapeutic advances targeting its downstream effects. This has led to a steady increase in survival over the past few decades. The recent development of disease‐modifying drugs targeting the underlying CFTR mutation has revolutionized treatment for CF.
John B. Palla
wiley   +1 more source

Trypsin IV, a novel agonist of protease-activated receptors 2 and 4 [PDF]

, 2004
Certain serine proteases signal to cells by cleaving protease-activated receptors (PARs) and thereby regulate hemostasis, inflammation, pain and healing. However, in many tissues the proteases that activate PARs are unknown.
Amadesi, Silvia, Grady, E. F., Bunnett, N. W., Cottrell, Graeme S.   +3 more
core   +1 more source

Neonatal screening for cystic fibrosis in São Paulo State, Brazil: a pilot study

Brazilian Journal of Medical and Biological Research, 2009
Cystic fibrosis is one of the most common autosomal recessive hereditary diseases in the Caucasian population, with an incidence of 1:2000 to 1:3500 liveborns. More than 1000 mutations have been described with the most common being F508del.
R. Rodrigues, P.K.R. Magalhaes, M.I.M. Fernandes, C.S. Gabetta, A.F. Ribeiro, K.P. Pedro, F. Valdetaro, J.L.F. Santos, R.M. de Souza, A. Pazin Filho, L.M.Z. Maciel   +10 more
doaj  

Cystic fibrosis year in review 2023

Pediatric Pulmonology, Volume 59, Issue 12, Page 3106-3116, December 2024.
Abstract This past year, there were many important advances for patients with cystic fibrosis (CF). Of the many publications related to CF in 2023, there was further evaluation of highly effective modulator therapy, new assessments and guidelines for clinical manifestations and therapies for CF, advances in newborn screening and diagnosis, and ...
David V. Swetland, Adrienne P. Savant
wiley   +1 more source

Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines; CFPAC-1 and CAPAN-1 [PDF]

, 1991
Proteins with trypsin-like immunoreactivity (first detected by a specific immunoenzymatic assay) were isolated from CAPAN-1 and CFPAC-1 cell culture-conditioned media by chromatography on an immunoadsorbent prepared with a polyclonal antibody directed ...
Figarella, C., F. Clemente, Schoumacher, R.A., B. Miszczuk-Jamska, O. Guy-Crotte, Amouric, M., C. Figarella, M. Amouric, Miszczuk-Jamska, B., Merten, M., Guy-Crotte, O., Clemente, F., R.A. Schoumacher, M. Merten   +13 more
core   +1 more source